DK2518509T3 - Molekylær prognose og klassificering af malignt melanom på basis af markører fra listen RGS1, NCOA3, SPP1, PHIP - Google Patents

Molekylær prognose og klassificering af malignt melanom på basis af markører fra listen RGS1, NCOA3, SPP1, PHIP

Info

Publication number
DK2518509T3
DK2518509T3 DK12177684.3T DK12177684T DK2518509T3 DK 2518509 T3 DK2518509 T3 DK 2518509T3 DK 12177684 T DK12177684 T DK 12177684T DK 2518509 T3 DK2518509 T3 DK 2518509T3
Authority
DK
Denmark
Prior art keywords
ncoa3
rgs1
phip
spp1
markers
Prior art date
Application number
DK12177684.3T
Other languages
English (en)
Inventor
Mohammed Kashani-Sabet
Christopher Haqq
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of DK2518509T3 publication Critical patent/DK2518509T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/5743Specifically defined cancers of skin, e.g. melanoma
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/112Disease subtyping, staging or classification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/136Screening for pharmacological compounds
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/56Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DK12177684.3T 2008-03-05 2009-03-05 Molekylær prognose og klassificering af malignt melanom på basis af markører fra listen RGS1, NCOA3, SPP1, PHIP DK2518509T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3410908P 2008-03-05 2008-03-05
EP09718437.8A EP2257810B1 (en) 2008-03-05 2009-03-05 Molecular diagnosis and classification of malignant melanoma

Publications (1)

Publication Number Publication Date
DK2518509T3 true DK2518509T3 (da) 2014-08-18

Family

ID=41056372

Family Applications (2)

Application Number Title Priority Date Filing Date
DK09718437.8T DK2257810T3 (da) 2008-03-05 2009-03-05 Molekylær diagnose og klassificering af malignt melanom
DK12177684.3T DK2518509T3 (da) 2008-03-05 2009-03-05 Molekylær prognose og klassificering af malignt melanom på basis af markører fra listen RGS1, NCOA3, SPP1, PHIP

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK09718437.8T DK2257810T3 (da) 2008-03-05 2009-03-05 Molekylær diagnose og klassificering af malignt melanom

Country Status (10)

Country Link
US (2) US8492102B2 (da)
EP (2) EP2257810B1 (da)
CN (1) CN102037361A (da)
AU (1) AU2009221778A1 (da)
CA (1) CA2716357A1 (da)
DK (2) DK2257810T3 (da)
ES (2) ES2489840T3 (da)
NZ (1) NZ587750A (da)
PT (2) PT2257810E (da)
WO (1) WO2009111661A1 (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009221778A1 (en) 2008-03-05 2009-09-11 The Regents Of The University Of California Molecular diagnosis and classification of malignant melanoma
CN102089444A (zh) 2008-05-14 2011-06-08 德玛泰克国际公司 利用核酸分析方法来诊断黑素瘤和太阳能雀斑
CA2796942C (en) 2010-04-20 2019-09-24 Cornell University Method for diagnosing melanocytic proliferations
CN102998448A (zh) * 2011-09-09 2013-03-27 上海市计划生育科学研究所 来源于前列腺分泌液中的前列腺癌标记物
US20160222457A1 (en) 2012-11-14 2016-08-04 Mayo Foundation For Medical Education And Research Methods and materials for identifying malignant skin lesions
AU2014241995B2 (en) 2013-03-14 2020-01-16 Castle Biosciences, Inc. Methods for predicting risk of metastasis in cutaneous melanoma
CA2906523A1 (en) 2013-03-15 2014-09-25 Myriad Genetics, Inc. Genes and gene signatures for diagnosis and treatment of melanoma
CN103472234B (zh) * 2013-07-05 2015-01-07 武汉三鹰生物技术有限公司 一种酶联免疫检测及制备方法
CA2953016A1 (en) 2014-07-02 2016-01-07 Myriad Genetics, Inc. Genes and gene signatures for diagnosis and treatment of melanoma
US20170275700A1 (en) 2014-08-14 2017-09-28 Mayo Foundation For Medical Education And Research Methods and materials for identifying metastatic malignant skin lesions and treating skin cancer
WO2017196944A1 (en) 2016-05-10 2017-11-16 Mayo Foundation For Medical Education And Research Methods and materials for staging and treating skin cancer
AU2019222462A1 (en) 2018-02-14 2020-09-03 Dermtech, Inc. Novel gene classifiers and uses thereof in non-melanoma skin cancers
JP2022524641A (ja) 2019-03-26 2022-05-09 ダームテック,インク. 皮膚癌における新規な遺伝子分類子とその使用
CN110438229A (zh) * 2019-08-01 2019-11-12 上海交通大学 一种胃癌预后诊断生物标记物及其诊断试剂盒
CN113293214A (zh) * 2021-06-17 2021-08-24 深圳华因康基因科技有限公司 一种检测神经母细胞瘤复发转移基因wnt2扩增的引物探针及其应用
CN115786504B (zh) * 2022-08-31 2023-09-19 中国人民解放军总医院京南医疗区 Hspa4抑制剂在治疗黑素瘤中的应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR6457315D0 (pt) 1963-03-05 1973-08-09 Yuki Kagaku Kogyo Kabush Tokyo Composicao pesticida
US3366308A (en) 1966-04-11 1968-01-30 Archer Products Inc Collapsible container
US4452720A (en) 1980-06-04 1984-06-05 Teijin Limited Fluorescent composition having the ability to change wavelengths of light, shaped article of said composition as a light wavelength converting element and device for converting optical energy to electrical energy using said element
US4439356A (en) 1981-03-03 1984-03-27 Syva Company Unsymmetrical fluorescein derivatives
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5330900A (en) 1987-12-31 1994-07-19 Tropix, Inc. Chemiluminescent 3-(substituted adamant-2'-ylidene) 1,2-dioxetanes
US5010175A (en) 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
US5066580A (en) 1988-08-31 1991-11-19 Becton Dickinson And Company Xanthene dyes that emit to the red of fluorescein
US5227487A (en) 1990-04-16 1993-07-13 Molecular Probes, Inc. Certain tricyclic and pentacyclic-hetero nitrogen rhodol dyes
IE66205B1 (en) 1990-06-14 1995-12-13 Paul A Bartlett Polypeptide analogs
US5650489A (en) 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
US5750409A (en) 1991-11-18 1998-05-12 Boehringer Mannheim Gmbh Pentacyclic compounds and their use as absorption or fluorescent dyes
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5885527A (en) 1992-05-21 1999-03-23 Biosite Diagnostics, Inc. Diagnostic devices and apparatus for the controlled movement of reagents without membrances
US5288514A (en) 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5593853A (en) 1994-02-09 1997-01-14 Martek Corporation Generation and screening of synthetic drug libraries
US5539083A (en) 1994-02-23 1996-07-23 Isis Pharmaceuticals, Inc. Peptide nucleic acid combinatorial libraries and improved methods of synthesis
US6447796B1 (en) 1994-05-16 2002-09-10 The United States Of America As Represented By The Secretary Of The Army Sustained release hydrophobic bioactive PLGA microspheres
US5525735A (en) 1994-06-22 1996-06-11 Affymax Technologies Nv Methods for synthesizing diverse collections of pyrrolidine compounds
US5549974A (en) 1994-06-23 1996-08-27 Affymax Technologies Nv Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof
US5569588A (en) 1995-08-09 1996-10-29 The Regents Of The University Of California Methods for drug screening
US5847162A (en) 1996-06-27 1998-12-08 The Perkin Elmer Corporation 4, 7-Dichlororhodamine dyes
US6080852A (en) 1996-06-27 2000-06-27 The Perkin-Elmer Corporation 4,7-dichlororhodamine dyes
US6008379A (en) 1997-10-01 1999-12-28 The Perkin-Elmer Corporation Aromatic-substituted xanthene dyes
US5936087A (en) 1997-11-25 1999-08-10 The Perkin-Elmer Corporation Dibenzorhodamine dyes
MXPA01009073A (es) 1999-03-10 2002-05-06 Phogen Ltd Suministro de acidos nucleicos y proteinas a las celulas.
US20020155440A1 (en) * 2000-12-19 2002-10-24 Ljubimova Julia Y. Using overexpression of laminin alpha 4 subunit as a diagnostic and prognostic indicator of malignant tumors
US20020130430A1 (en) 2000-12-29 2002-09-19 Castor Trevor Percival Methods for making polymer microspheres/nanospheres and encapsulating therapeutic proteins and other products
US7247426B2 (en) * 2001-08-02 2007-07-24 Agilent Technologies, Inc. Classifying cancers
US7060498B1 (en) 2001-11-28 2006-06-13 Genta Salus Llc Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers
US7141540B2 (en) 2001-11-30 2006-11-28 Genta Salus Llc Cyclodextrin grafted biocompatible amphilphilic polymer and methods of preparation and use thereof
US20050222064A1 (en) 2002-02-20 2005-10-06 Sirna Therapeutics, Inc. Polycationic compositions for cellular delivery of polynucleotides
WO2004048545A2 (en) 2002-11-26 2004-06-10 University Of Massachusetts DELIVERY OF siRNAs______________________________________________
EP1709195B1 (en) 2003-12-19 2014-01-22 Novartis Vaccines and Diagnostics, Inc. Cell transfecting formulations of small interfering rna, related compositions and methods of making and use
EP2145957B1 (en) 2004-04-20 2013-12-25 Marina Biotech, Inc. Compositions for enhancing delivery of double-stranded RNA to regulate gene expression in mammalian cells
US7514530B2 (en) 2004-04-26 2009-04-07 Centre National De La Recherche Scientifique Peptide carrier for delivering siRNA into mammalian cells
EP2062049B1 (en) * 2006-09-06 2014-04-30 The Regents of the University of California Molecular diagnosis and classification of malignant melanoma
US7615349B2 (en) * 2006-09-07 2009-11-10 H. Lee Moffitt Cancer Center And Research Institute, Inc. Melanoma gene signature
AU2009221778A1 (en) 2008-03-05 2009-09-11 The Regents Of The University Of California Molecular diagnosis and classification of malignant melanoma

Also Published As

Publication number Publication date
EP2518509A2 (en) 2012-10-31
PT2257810E (pt) 2013-08-22
US20130344481A1 (en) 2013-12-26
EP2518509B1 (en) 2014-05-14
ES2489840T3 (es) 2014-09-02
US8492102B2 (en) 2013-07-23
CN102037361A (zh) 2011-04-27
EP2257810A1 (en) 2010-12-08
US20110123997A1 (en) 2011-05-26
WO2009111661A1 (en) 2009-09-11
EP2257810A4 (en) 2011-06-08
AU2009221778A1 (en) 2009-09-11
ES2424329T3 (es) 2013-10-01
CA2716357A1 (en) 2009-09-11
WO2009111661A9 (en) 2010-06-10
NZ587750A (en) 2012-10-26
EP2257810B1 (en) 2013-06-05
EP2518509A3 (en) 2013-01-23
DK2257810T3 (da) 2013-07-15
PT2518509E (pt) 2014-09-01

Similar Documents

Publication Publication Date Title
DK2518509T3 (da) Molekylær prognose og klassificering af malignt melanom på basis af markører fra listen RGS1, NCOA3, SPP1, PHIP
EP2108172A4 (en) ADVERTISING RECOMMENDATION BASED ON SOCIAL RELATIONS
BRPI0907440A2 (pt) estadiamento molecular de câncer de cólon em estágio ii e iii prognóstico
HK1132808A1 (en) Contextual mobile local search based on social network vitality information
DE602008004610D1 (de) Netzzustandserfassung und -reproduktion
BRPI1015948A2 (pt) propagação de informação promocional em uma rede social.
NL2001666A1 (nl) Multiple simultaneous frequency detection.
DE602008005376D1 (de) Tragbares Informationsendgerät
BRPI0819811A2 (pt) Identificação de setor usando assinaturas de parâmetros de setor
BRPI0917858A2 (pt) conjunto de pás fixo de turbomáquina, e turbomáquina.
DK2600656T3 (da) Systeminformationsopdateringer i LTE
DK2062049T3 (da) Molekulær diagnose og klassificering af malignt melanoma
DK3176270T3 (da) Forudsigelse af melanomcancerprognose
DK2257301T3 (da) Immunterapi baseret på allogene cancerceller.
DK2197492T3 (da) Hidtil ukendte præparater på basis af taxoider
FR2932482B1 (fr) Nouveaux derives de (phenyl-3,6-dihydro-2h-pyridinyl)- (piperazinyl ponte)-1-alcanone et leur utilisation comme inhibiteurs de p75
BRPI0807769A2 (pt) Copolímero grafitizado.
FI20075484A (fi) Tilaajan tunnistetietojen kuljettaminen
DK2306995T3 (da) Antitumoregenskaber af umodificerede proteaseinhibitorer
DK2171083T3 (da) Biosensing af molekylær konformation
ES1069126Y (es) Soporte digital para publicidad o informacion
IT1401075B1 (it) Pedonale di passaggio sopraelevata ad alta tecnologia
DK2367447T3 (da) Havregrynsmorgenmadsprodukt fremstillet af små havregryn og fine dele
DE112009003295A5 (de) Informationsübertragung für sich bewegende benutzer
FI7929U1 (fi) Kelaatit ja leimausreagenssit